Table 1. Declined human kidney characteristics and experimental conditions.

Donor demographics, donor type; donation after brain death (DBD), donation after circulatory death (DCD), reason for decline, warm ischemic time, cold ischemic time, duration of ex vivo normothermic perfusion (NMP), mean renal blood flow (RBF), total urine output, macroscopic appearance, NPs, and time to administration of NPs.

Case 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8
Donor age
(years)
5725446845646557
Donor type
(DBD/DCD)
DCDDBDDCDDBDDBDDCDDCDDCD
Left/right kidneyLeftRightRightRightLeftLeftLeftLeft
Reason for declinePoor in situ
perfusion
MalignancySuspected
malignancy
Suspected
malignancy
Poor in situ
perfusion + prolonged
agonal phase
Suspected
malignancy
Histological
changes
consistent with
diabetes
Damage to
ureter and
artery
Warm ischemic
time (min)
1313121411
Cold ischemic time
(hour:min)
13:1317:1734:3716:0322:3827:0518:2025:58
NMP duration
(hour:min)
4:306:505:455:005:008:308:308:30
Mean RBF
(ml/min per 100 g)
88.0 ± 19.6123.7 ± 35.291.6 ± 23.967.9 ± 31.783.5 ± 35.575.0 ± 22.177.3 ± 25.480.7 ± 37.7
Total urine
output (ml)
1777301071045373598451257
Macroscopic
appearance
ModerateModerateModerateModerateModerateExcellentExcellentModerate
NP typeCD31-NPControl-NPCD31-NP +
Control-NP
CD31-NP +
Control-NP
CD31-NP +
Control-NP
CD31-NP +
Control-NP
CD31-NP +
Control-NP
CD31-NP +
Control-NP
NP circulating
concentration
4 μg/ml4 μg/ml10 μg/ml50 μg/ml100 μg/ml50 μg/ml50 μg/ml50 μg/ml
NP administration
time (from start of
perfusion)
30 min50 min45 min75 min60 min30 min30 min30 min